ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "N-Palmitoyl Glutamine: Fitness Mediator 11/13/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.
Article Links:
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. (Circulation)
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. (Circulation)
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. (European heart journal)
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. (Journal of cardiac failure)
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/
Featured Articles
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221593
Summary: This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221589
Summary: This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222955
Summary: This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224169
Summary: This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222953
Summary: This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.
Transcript
Today’s date is November 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.
Article number two. N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.
Article number three. Cellular and molecular imaging of coronary atherosclerosis: clinical applications. This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.
Article number four. Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.
Article number five. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.
Thank you for listening. Don’t forget to subscribe.
Keywords
pediatric cardiology, subclinical atrial fibrillation, cardiac magnetic resonance, major bleeding, waitlist outcomes, cardiometabolic health, heart transplant, aspirin, apixaban, cellular imaging, atherosclerosis, metabolomics, congenital heart disease, ARTESiA trial, prognosis, risk stratification, atheroma, cardiorespiratory fitness, tricuspid regurgitant fraction, Fontan circulation, plasma, molecular imaging, tricuspid regurgitation, N-Palmitoyl Glutamine, coronary artery disease.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post N-Palmitoyl Glutamine: Fitness Mediator 11/13/25 first appeared on Cardiology Today.
Article Links:
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. (Circulation)
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. (Circulation)
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. (European heart journal)
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. (Journal of cardiac failure)
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/
Featured Articles
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221593
Summary: This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221589
Summary: This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222955
Summary: This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224169
Summary: This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222953
Summary: This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.
Transcript
Today’s date is November 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.
Article number two. N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.
Article number three. Cellular and molecular imaging of coronary atherosclerosis: clinical applications. This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.
Article number four. Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.
Article number five. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.
Thank you for listening. Don’t forget to subscribe.
Keywords
pediatric cardiology, subclinical atrial fibrillation, cardiac magnetic resonance, major bleeding, waitlist outcomes, cardiometabolic health, heart transplant, aspirin, apixaban, cellular imaging, atherosclerosis, metabolomics, congenital heart disease, ARTESiA trial, prognosis, risk stratification, atheroma, cardiorespiratory fitness, tricuspid regurgitant fraction, Fontan circulation, plasma, molecular imaging, tricuspid regurgitation, N-Palmitoyl Glutamine, coronary artery disease.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post N-Palmitoyl Glutamine: Fitness Mediator 11/13/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust